Research News

About 95% of participants achieved a measurable immune response after vaccination, according to study led by a KU School of Medicine professor and published in JAMA Oncology.

The five-year, NIH-funded COMET clinical trial is the largest of its kind to compare aerobic, resistance training or a combination of both while looking at cognition in older adults.

Equipment upgrade provides cutting-edge resources to researchers across the region

The method offers a powerful alternative to conventional flow cytometry based on blood DNA rather than intact living cells

The study, part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative, is designed to determine the long-term effects of COVID-19 and to understand why some adults develop long COVID and others do not.

The University of Kansas Clinical Research Center (KU CRC), a dedicated clinical trials facility with support from a Johnson County sales tax, celebrates it's 10 year anniversary.

Axicabtagene ciloleucel, known by the brand name Yescarta, is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.

The pandemic continues, but so does research and education.

Along with leaders from Frontiers, Children’s Mercy Kansas City and the University of Kansas Medical Center, the group discussed how to adapt or “translate” medical research into useful treatments for patients.

A symposium, held virtually Oct. 27-28, allowed scientists to learn about, and share, the latest research in PKD.

Barney Graham, the architect of Moderna and Pfizer vaccine, is honored in a Washington, D.C. celebration.

Want to preserve your memory as you age? Reach for an avocado.

For people who are overweight, obese or excessively obese, the threat of COVID-19 looms large. So, University of Kansas Medical Center researchers are testing obesity as a variable in a clinical trial and continuing research on obesity in general.

Renewal of five-year grant will provide funding for the KU Alzheimer’s Disease Research Center through 2026.

Trikafta can provide additional benefit for CF patients who have genetic mutations that made them eligible for previously approved CFTR modulators.

These guidelines will help physicians make informed decisions with patients by understanding their individual risks and outlining a plan for their care.

The study evaluated a one-time infusion of Yescarta compared with standard of care in patients who had relapsed or had refractory LBCL after frontline treatment.

The KU ADC looks to increase diversity across all its numerous studies with a goal of making African Americans and Latinos at least 20 percent of the trial's participants across all sites.

Research looks to understand the safety and efficacy of the COVID-19 vaccine in individuals receiving immunosuppressive and cytotoxic treatments.

The FSHD CTRN, an international network of academic research centers, uses the expertise and infrastructure of its members to streamline clinical trial research.

The University of Kansas Cancer Center is calling for public attention to this issue to prevent cancer deaths.

Leading the multi-site clinical trial, Carol Fabian, M.D. and her team plan to enroll 120 women ages 45 to 60 who are at increased risk for breast cancer.

A new mobile application created by The University of Kansas Cancer Center allows anyone to identify potential clinical trials right here at KU and quickly communicate with the clinical trials team.

Three new outpatient treatments will be tested at the University of Kansas Medical Center in efforts to broaden options for COVID-19 patients. These new treatments may make it easier to receive COVID-19 treatment outside a hospital, as they include an oral pill, an injection and a medication that can be inhaled through a home nebulizer.

Two new monoclonal antibody treatments for outpatients with COVID-19 are being tested at the University of Kansas Medical Center. Known as BRII 196 and 198 and produced by Brii Biosciences, these investigational treatments are both monoclonal antibodies designed to block the ACE receptor.

Adam Rouse, M.D., Ph.D., an assistant professor and director of basic research in the Department of Neurosurgery, sees basic science emerging as a key player in the fight against the pandemic

Researchers from The University of Kansas Cancer Center are involved in the presentation of nearly 50 research studies at the 62nd American Society of Hematology (ASH) Annual Meeting.

Female physicians are more likely to pursue careers in academic medicine than their male counterparts but are less likely to be promoted to senior faculty and leadership positions, and that gender gap is no narrower than it was 20 years ago, according to a study published by researchers at KU Medical Center in the NEJM.

Men with cancer and COVID-19 may be at significantly higher risk for severe symptoms and even death as compared to females fighting both, a University of Kansas Cancer Center research team has found after reviewing multiple studies.

The physician-scientist training program at the University of Kansas Medical Center, which enables students to earn both a medical degree and a doctoral degree in a biomedical science, is now recognized as one of the most prestigious such programs in the country.

The American Society for Gravitational and Space Research (ASGR) recognized Joseph S. Tash, emeritus professor of molecular and integrative physiology at the University of Kansas Medical Center, with its prestigious Founder’s Award.

The Airways Clinical Research Centers Network (ACRC), the research arm of the American Lung Association, named the University of Kansas Medical Center a consortium hub. The change will give KU Medical Center the responsibility to mentor and lead other universities in its group in lung-health research, including COVID-19 research.

The University of Kansas Medical Center has been chosen to receive a grant from the National Institutes of Health (NIH) through the RADx-UP program to support projects designed to rapidly implement COVID-19 testing strategies in populations disproportionately affected by the pandemic.

The University of Kansas Medical Center will be participating in a unique nationwide clinical trial that will allow for the testing of multiple agents to fight COVID-19. Known as ACTIV-2 (Adapt Out COVID), this trial is part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines effort announced by the National Institutes of Health (NIH) this spring.

Faculty at the University of Kansas School of Nursing are taking a unique look at the value of nursing by combining electronic health records, human resource records and other data to measure the effects of nursing on pain management.

"These awards provide our investigators with opportunities to move quickly toward developing research programs aimed at COVID-19 mitigation and treatment." --Peter Smith, Ph.D., senior associate vice chancellor for research, KU School of Medicine

Pioneering geneticist Merlin G. Butler, M.D., Ph.D., keeps pushing the boundaries of science

The University of Kansas Medical Center and Children's Mercy Kansas City announced that they will be leading the regional efforts of a nationwide clinical trial brought through the COVID-19 Prevention Network to test the COVID-19 vaccine AZD1222, developed by Oxford University and purchased by AstraZeneca.

A private laboratory operating on the campus of the University of Kansas Medical Center conducts COVID-19 tests. Its founder says it's a service to his community.

Frontiers: University of Kansas Clinical and Translational Science Institute has awarded three pilot grants to scientists studying COVID-19.

Cancer patients undergoing treatment at The University of Kansas Cancer Center don’t have to worry about getting a test for the novel coronavirus that causes COVID-19. The research arm of the KU Cancer Center stepped up to allow patients to opt-in to a study that provided the test in recent weeks and also covered its cost. It is just one of the many ways the KU Cancer Center is working to fight the pandemic.

Five undergraduate and five graduate students from the University of Kansas Medical Center showcased their research at the Kansas Capitol during two separate events in spring 2020. Students discussed the posters illustrating their research with lawmakers and the general public.

The Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO HCQ) trial is accompanied by a registry that will create a community of health care workers who have expressed interest in contributing to the scientific community's understanding of the impact of COVID-19.

SHARPhub was established in 2018 to help researchers move biomedical discoveries and technologies out of the laboratory and into the commercial market, where they can be used to improve human health.

The University of Kansas Cancer Center will receive an additional $5 million from the state budget for the KU Cancer Center Research Fund, approved by the Kansas legislature and signed by Governor Laura Kelly. These funds will be crucial to the KU Cancer Center’s competitive application for National Cancer Institute (NCI) comprehensive cancer center designation.

Women with a high risk for breast cancer can be prescribed drugs to help reduce their risk of cancer, but many don’t take the drugs because of their problematic side effects.Researchers at The University of Kansas Cancer Center have identified a drug that may keep the preventive punch but lessen the strong side effects.

Dennis Owens, MD, PhD, leading psychiatry department’s new clinical trial research

Individuals who have an inherited condition that gives them high cholesterol regardless of diet or other lifestyle issues might one day benefit from the new drug APO(a)-I, which was tested at the University of Kansas Medical Center by Patrick M. Moriarty, M.D. Results were published in the New England Journal of Medicine in January 2020.

Dr. Prachee Avasthi, assistant professor of cell biology, and her team have published four scholarly articles on actin protein and how it affects cell cilia. This basic science may help with disease research in the future.

A new research unit that will greatly expand the capacity for scientists to conduct clinical trials opened at the University of Kansas Medical Center on Jan. 13. It is the first clinical and translational science unit (CTSU) on the main KU Medical Center campus in Kansas City, Kansas.

Check out the memorable news stories of 2019 at the University of Kansas Medical Center. Our year in review gives you a look back at the best of 2019.

The University of Kansas Center for Physical Activity and Weight Management conducts nationally funded studies based on weight loss and activity and also has an award-winning fee-for-service weight loss clinic.

KU Medical Center was one of the sites of a phase 3 trial that led to the approval of the drug, known by its brand name, Trikafta, by the U.S. Food and Drug Administration on October 21.

The All of Us Research Program visited the University of Kansas Medical Center as part of its quest to collect biomedical data from 1 million individuals across the United States in the next 10 years.

The Department of Occupational Therapy Education at the University of Kansas Medical Center has developed a national reputation of excellence for educating its students to become therapists who provide essential assessment and support skills that empower their patients with physical or mental disabilities to engage in everyday life activities.